1. history or current hospitalization for covid-19. 2. current need for hospitalization/immediate medical attention in a clinic/emergency room service 3. previous hypersensitivity, infusion related reaction, or adverse reaction to any monoclonal antibodies or known allergy to components of the imp or placebo. 4. receipt of any investigational or licensed vaccine for prevention of covid-19 at any time prior to entry into this study or expected administration immediately after enrollment. 5. current requirement or anticipated impending need for mechanical ventilation. 6. any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study. 7. received convalescent covid-19 plasma treatment any time prior to entry into this study. 8. receipt of systemic steroids (e.g., prednisone, dexamethasone) or inhaled steroids within 30 days prior to study entry, unless a stable dose is used for a chronic condition. 9. receipt of any imp in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of imp during the study follow-up period, or concurrent participation in another interventional study. 10. pregnant or breastfeeding women.

1. history or current hospitalization for covid-19. 2. current need for hospitalization/immediate medical attention in a clinic/emergency room service 3. previous hypersensitivity, infusion related reaction, or adverse reaction to any monoclonal antibodies or known allergy to components of the imp or placebo. 4. receipt of any investigational or licensed vaccine for prevention of covid-19 at any time prior to entry into this study or expected administration immediately after enrollment. 5. current requirement or anticipated impending need for mechanical ventilation. 6. any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study. 7. received convalescent covid-19 plasma treatment any time prior to entry into this study. 8. receipt of systemic steroids (e.g., prednisone, dexamethasone) or inhaled steroids within 30 days prior to study entry, unless a stable dose is used for a chronic condition. 9. receipt of any imp in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of imp during the study follow-up period, or concurrent participation in another interventional study. 10. pregnant or breastfeeding women.

history or current hospitalization for covid-19. current need for hospitalization/immediate medical attention in a clinic/emergency room service previous hypersensitivity, infusion related reaction, or adverse reaction to any monoclonal antibodies or known allergy to components of the imp or placebo. receipt of any investigational or licensed vaccine for prevention of covid-19 at any time prior to entry into this study or expected administration immediately after enrollment. current requirement or anticipated impending need for mechanical ventilation. any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study. received convalescent covid-19 plasma treatment any time prior to entry into this study. receipt of systemic steroids (e.g., prednisone, dexamethasone) or inhaled steroids within 30 days prior to study entry, unless a stable dose is used for a chronic condition. receipt of any imp in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of imp during the study follow-up period, or concurrent participation in another interventional study. pregnant or breastfeeding women.

history or current hospitalization for covid-19. current need for hospitalization/immediate medical attention in a clinic/emergency room service previous hypersensitivity, infusion related reaction, or adverse reaction to any monoclonal antibodies or known allergy to components of the imp or placebo. receipt of any investigational or licensed vaccine for prevention of covid-19 at any time prior to entry into this study or expected administration immediately after enrollment. current requirement or anticipated impending need for mechanical ventilation. any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study. received convalescent covid-19 plasma treatment any time prior to entry into this study. receipt of systemic steroids (e.g., prednisone, dexamethasone) or inhaled steroids within 30 days prior to study entry, unless a stable dose is used for a chronic condition. receipt of any imp in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of imp during the study follow-up period, or concurrent participation in another interventional study. pregnant or breastfeeding women.

1. history or current hospitalization for covid-19. 2. current need for hospitalization/immediate medical attention in a clinic/emergency room service 3. previous hypersensitivity, infusion related reaction, or adverse reaction to any monoclonal antibodies or known allergy to components of the imp or placebo. 4. receipt of any investigational or licensed vaccine for prevention of covid-19 at any time prior to entry into this study or expected administration immediately after enrollment. 5. current requirement or anticipated impending need for mechanical ventilation. 6. any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study. 7. received convalescent covid-19 plasma treatment any time prior to entry into this study. 8. receipt of systemic steroids (e.g., prednisone, dexamethasone) or inhaled steroids within 30 days prior to study entry, unless a stable dose is used for a chronic condition. 9. receipt of any imp in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of imp during the study follow-up period, or concurrent participation in another interventional study. 10. pregnant or breastfeeding women.

1. history or current hospitalization for covid-19. 2. current need for hospitalization/immediate medical attention in a clinic/emergency room service 3. previous hypersensitivity, infusion related reaction, or adverse reaction to any monoclonal antibodies or known allergy to components of the imp or placebo. 4. receipt of any investigational or licensed vaccine for prevention of covid-19 at any time prior to entry into this study or expected administration immediately after enrollment. 5. current requirement or anticipated impending need for mechanical ventilation. 6. any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study. 7. received convalescent covid-19 plasma treatment any time prior to entry into this study. 8. receipt of systemic steroids (e.g., prednisone, dexamethasone) or inhaled steroids within 30 days prior to study entry, unless a stable dose is used for a chronic condition. 9. receipt of any imp in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of imp during the study follow-up period, or concurrent participation in another interventional study. 10. pregnant or breastfeeding women.

1. history or current hospitalization for covid-19. 2. need for hospitalization/immediate medical attention in a clinic/emergency room service 3. previous adverse reaction to any monoclonal antibodies or known allergy to components of the imp or placebo. 4. receipt of any investigational or licensed vaccine for prevention of covid-19 at any time prior to entry into this study. 5. requirement or anticipated impending need for mechanical ventilation. 6. any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study. 7. received convalescent covid-19 plasma treatment any time prior to entry into this study. 8. pregnant or breastfeeding women. 9. receipt of any imp in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of imp during the study follow-up period, or concurrent participation in another interventional study.

1. history or current hospitalization for covid-19. 2. need for hospitalization/immediate medical attention in a clinic/emergency room service 3. previous adverse reaction to any monoclonal antibodies or known allergy to components of the imp or placebo. 4. receipt of any investigational or licensed vaccine for prevention of covid-19 at any time prior to entry into this study. 5. requirement or anticipated impending need for mechanical ventilation. 6. any significant disease, disorder or finding that may increase risk to the participant that might affect his/her ability to participate in this study. 7. received convalescent covid-19 plasma treatment any time prior to entry into this study. 8. pregnant or breastfeeding women. 9. receipt of any imp in the previous 90 days or 5 half lives (whichever is longer), or expected receipt of imp during the study follow-up period, or concurrent participation in another interventional study.